Richard H. Chapman - Publications, H-index & Citations

Richard H. Chapman

Innovation and Value Research

37H指数

111论文数

1.2W被引数

收录论文 34

发表时间

HTA Evidence in Rare Diseases: Just Rare or Also Special?HTA证据在罕见病中的应用：仅仅是罕见，还是具有特殊性？

PharmacoEconomics

IF4.6

2025-09-09

OAAI

Anirban Basu; Simu K. Thomas; Richard H. Chapman; Jason Spangler

Patient-Informed Value Elements in Cost-Effectiveness Analyses of Major Depressive Disorder Treatment: A Literature Review and Synthesis

VALUE IN HEALTH

IF6

2025-03-01

PREAI

Slejko, Julia F.; Mattingly Ii, T. Joseph; Wilson, Alexandra; Xie, Richard; Chapman, Richard H.; Amill-Rosario, Alejandro; Dosreis, Susan

Cost-Effectiveness of Nadofaragene Firadenovec and Pembrolizumab in Bacillus Calmette-Guerin Immunotherapy Unresponsive Non-Muscle Invasive Bladder Cancer Nadofaragene Firadenovec和Pembrolizumab在卡介苗-格林芽孢杆菌免疫疗法无反应的非肌肉浸润性膀胱癌中的成本效益

VALUE IN HEALTH

IF6

2023-06-01

PREAI

Joshi, Mrinmayee; Atlas, Steven J.; Beinfeld, Molly; Chapman, Richard H.; Rind, David M.; Pearson, Steven D.; Touchette, Daniel R.

Preferences for Treatments for Major Depressive Disorder: Formative Qualitative Research Using the Patient Experience

PATIENT-PATIENT CENTERED OUTCOMES RESEARCH

IF3.1

2022-09-19

OAAI

dosReis, Susan; Bozzi, Laura M.; Butler, Beverly; Xie, Richard Z.; Chapman, Richard H.; Bright, Jennifer; Malik, Erica; Slejko, Julia F.

Does Cost-Effectiveness Analysis Overvalue Potential Cures? Exploring Alternative Methods for Applying a Shared Savings Approach to Cost Offsets

VALUE IN HEALTH

IF6

2021-06-01

OAAI

Chapman, Richard H.; Kumar, Varun M.; Whittington, Melanie D.; Pearson, Steven D.

Developing a Framework for the Health Technology Assessment of Histology-independent Precision Oncology Therapies

APPLIED HEALTH ECONOMICS AND HEALTH POLICY

IF3.3

2021-05-24

PREAI

Gaultney, Jennifer G.; Bouvy, Jacoline C.; Chapman, Richard H.; Upton, Alexander J.; Kowal, Stacey; Bokemeyer, Carsten; Sola-Morales, Oriol; Wolf, Jurgen; Briggs, Andrew H.

Cost-Effectiveness of Ivacaftor Therapy for Treatment of Cystic Fibrosis Patients With the G551D Gating Mutation

VALUE IN HEALTH

IF6

2020-10-01

OAAI

Wherry, Kael; Williamson, Ian; Chapman, Richard H.; Kuntz, Karen M.

Modeling Medicaid and Medicare Savings from Reduced Poverty and Disability to Promote Investment in Mental Health and Substance Use Interventions in the USA

APPLIED HEALTH ECONOMICS AND HEALTH POLICY

IF3.3

2020-03-18

PREAI

Counts, Nathaniel Z.; Gionfriddo, Paul; Chapman, Richard H.

Important Considerations in Modeling the Cost-Effectiveness for the First Food and Drug Administration-Approved Gene Therapy and Implications for Future One-Time Therapies Reply

VALUE IN HEALTH

IF6

2019-08-01

OAAI

Zimmermann, Marita; Lubinga, Solomon J.; Banken, Reiner; Rind, David; Cramer, Geri; Synnott, Patricia G.; Chapman, Richard H.; Khan, Sonya; Carlson, Josh

United States Valuation of EQ-5D-5L Health States Using an International Protocol

VALUE IN HEALTH

IF6

2019-08-01

237

OAAI

Pickard, A. Simon; Law, Ernest H.; Jiang, Ruixuan; Pullenayegum, Eleanor; Shaw, James W.; Xie, Feng; Oppe, Mark; Boye, Kristina S.; Chapman, Richard H.; Gong, Cynthia L.; Balch, Alan; Busschbach, Jan J. V.

New Cost-Effectiveness Methods to Determine Value-Based Prices for Potential Cures: What Are the Options?

VALUE IN HEALTH

IF6

2019-06-01

OAAI

Pearson, Steven D.; Ollendorf, Daniel A.; Chapman, Richard H.

Current Value Frameworks-What's New?

VALUE IN HEALTH

IF6

2019-06-01

OAAI

Willke, Richard J.; Chapman, Richard H.; Seidman, Joshua J.; Schnipper, Lowell E.; Gleason, Patrick P.

COST-EFFECTIVENESS OF NUSINERSEN AND ONASEMNOGENE ABEPARVOVEC FOR INFANTILE-ONSET SPINAL MUSCULAR ATROPHY (TYPE I SMA) IN THE US

VALUE IN HEALTH

IF6

2019-05-01

OAAI

Thokala, P.; Stevenson, M.; Kumar, V. M.; Ren, S.; Chapman, R.; Ellis, A.; Rind, D.

Impact of Abuse Deterrent Formulations of Opioids in Patients With Chronic Pain in the United States: A Cost-Effectiveness Model 美国慢性疼痛患者阿片类药物滥用威慑制剂的影响: 成本效益模型

VALUE IN HEALTH

IF6

2019-04-01

OAAI

Kumar, Varun M.; Agboola, Foluso; Synnott, Patricia G.; Segel, Celia; Webb, Maggie; Ollendorf, Daniel A.; Banken, Reiner; Chapman, Richard H.

Cost Utility of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease

VALUE IN HEALTH

IF6

2019-02-01

OAAI

Zimmermann, Marita; Lubinga, Solomon J.; Banken, Reiner; Rind, David; Cramer, Geri; Synnott, Patricia G.; Chapman, Richard H.; Khan, Sonya; Carlson, Josh

Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia

JAMA PEDIATRICS

IF18

2018-12-01

OAAI

Whittington, Melanie D.; McQueen, R. Brett; Ollendorf, Daniel A.; Kumar, Varun M.; Chapman, Richard H.; Tice, Jeffrey A.; Pearson, Steven D.; Campbell, Jonathan D.

Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis

CNS DRUGS

IF7.4

2018-08-23

PREAI

Zimmermann, Marita; Brouwer, Elizabeth; Tice, Jeffrey A.; Seidner, Matt; Loos, Anne M.; Liu, Shanshan; Chapman, Richard H.; Kumar, Varun; Carlson, Josh J.

Evaluating and Valuing Drugs for Rare Conditions: No Easy Answers

VALUE IN HEALTH

IF6

2018-05-01

OAAI

Ollendorf, Daniel A.; Chapman, Richard H.; Pearson, Steven D.

Cost-Effectiveness of Sacubitril-Valsartan in Patients Who Have Heart Failure With Reduced Ejection Fraction RESPONSE

ANNALS OF INTERNAL MEDICINE

IF15.2

2017-04-18

PREAI

Sandhu, Alexander T.; Ollendorf, Daniel A.; Chapman, Richard H.; Pearson, Steven D.; Heidenreich, Paul A.